Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an update.
Neuren Pharmaceuticals Limited has announced an update regarding its ongoing share buy-back program, with a total of 3,939,424 securities bought back before the previous day and an additional 60,082 securities purchased on the previous day. This buy-back initiative is part of the company’s strategy to enhance shareholder value and optimize its capital structure, reflecting confidence in its business prospects and commitment to returning capital to shareholders.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is known for its work in creating treatments for conditions such as Rett syndrome and Fragile X syndrome, targeting significant unmet medical needs in the market.
Average Trading Volume: 722,917
Technical Sentiment Signal: Buy
Current Market Cap: A$1.77B
Find detailed analytics on NEU stock on TipRanks’ Stock Analysis page.